Open AccessThe Proton Pump Inhibitors Use and COVID-19 from Prior to Vaccination Perspective: A Review
Author(s) -
Dorota Ksiądzyna,
Adam Szeląg
Publication year - 2022
Publication title -
digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.879
H-Index - 66
eISSN - 1421-9875
pISSN - 0257-2753
DOI - 10.1159/000527501
Subject(s) - medicine , intensive care medicine , disease , vaccination , covid-19 , concomitant , coronavirus , pneumonia , immunology , infectious disease (medical specialty)
The coronavirus infectious disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has been a huge challenge, affecting directly or indirectly the human race worldwide. Many COVID-19-related risk factors have been identified. Various drugs, including proton pump inhibitors (PPIs), have been claimed to increase the risk of acquiring or affecting the outcome of COVID-19 prior to the availability of vaccines. The aim of this review was to summarize the uncertain role of PPI use on the SARS-CoV-2 infection and COVID-19 clinical course, including both some well-established and presumptive indications to these potent inhibitors of gastric acid secretion, before vaccinations against COVID-19 were implemented on a massive scale.